View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPalatin Technologies 配当と自社株買い配当金 基準チェック /06Palatin Technologies配当金を支払った記録がありません。主要情報n/a配当利回り-178.0%バイバック利回り総株主利回り-178.0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 14Palatin Technologies, Inc. to Report Q3, 2026 Results on May 13, 2026Palatin Technologies, Inc. announced that they will report Q3, 2026 results on May 13, 2026お知らせ • Nov 06Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $15.799999 million.Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $15.799999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,430,769 Price\Range: $6.5 Security Name: Series J Common Warrants Security Type: Equity Warrant Securities Offered: 2,430,769 Security Name: Series K Common Warrants Security Type: Equity Warrant Securities Offered: 2,430,769 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 2,430,769お知らせ • Oct 01Palatin Technologies, Inc. has filed a Follow-on Equity Offering.Palatin Technologies, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,492,537 Security Name: Series J Common Warrants Security Type: Equity Warrant Securities Offered: 1,492,537 Security Name: Series K Common Warrants Security Type: Equity Warrant Securities Offered: 1,492,537 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 1,492,537お知らせ • Jul 15Palatin Technologies, Inc. Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of ObesityPalatin Technologies, Inc. announced strong preclinical results for PL7737, an oral selective melanocortin-4 receptor (MC4R) agonist, showing effectiveness in rodent models of obesity. The preclinical study evaluated the weight loss effects of three oral doses of PL7737, both alone and in combination with tirzepatide (a GLP-1/GIP agonist), in a diet-induced obese (DIO) rat model. After 4 days of treatment, all results were statistically significant compared to vehicle control: PL7737 - Middle Dose: 5% weight loss, PL7737 - High Dose: 10% weight loss, Tirzepatide Alone: 5% weight loss,PL7737 Middle Dose + Tirzepatide: 11% weight loss. PL7737 High Dose + TirzepATide: 15% weight loss. Earlier this year, Palatin reported positive Phase 2 results from a study evaluating the combination of bremelanotide (an MC4R agonist) and tirzepatide (a GLP-1/G IP agonist). The study met its primary endpoint over the 8-week treatment period with highly statistically significant results. Additionally, Palatin announced that the FDA granted orphan drug designation to PL7737 for the treatment of leptin receptor (LEPR) deficiency-related obesity, a rare genetic disorder that disrupts MC4R signaling due to mutations in the LEPR gene. The leptin-melanocortin pathway, located in the hypothalamus, regulates hunger, energy balance, and body weight.お知らせ • Jul 10Nyse American LLC Affirms the Decision of the Staff of NYSE American to Initiate Delisting Proceedings of the Palatin Technologies, Inc. Common StockOn July 7, 2025, Palatin Technologies, Inc. received written notification from NYSE American LLC stating that a Listing Qualifications Panel of the Exchange’s Committee for Review had unanimously determined to affirm the decision of the staff of NYSE American to initiate delisting proceedings of the Company’s common stock pursuant to Sections 1003(a) and 1003(f)(v) of the NYSE American Company Guide. A hearing on the proposed delisting was held before the Panel on June 18, 2025. The Company intends to exercise its right to have the full Committee for Review reconsider the Panel’s decision. A written request for such review must be submitted and received by the Exchange within 15 calendar days of the date of Panel’s written notification. The Company is actively working to resolve the NYSE American listing deficiencies prior to the appeal hearing before the full Committee for Review, which is expected to take place in late August or September 2025.お知らせ • Jun 19Palatin Technologies, Inc., Annual General Meeting, Jul 25, 2025Palatin Technologies, Inc., Annual General Meeting, Jul 25, 2025.お知らせ • Jun 14Palatin Technologies, Inc. announced that it has received $0.34 million in fundingOn June 13, 2025, Palatin Technologies, Inc. closed the transaction.Board Change • May 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. Independent Director Tony Manning was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.決済の安定と成長配当データの取得安定した配当: PTNの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: PTNの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Palatin Technologies 配当利回り対市場PTN 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (PTN)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.7%業界平均 (Biotechs)2.4%アナリスト予想 (PTN) (最長3年)n/a注目すべき配当: PTNは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: PTNは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: PTNの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: PTNが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/11/05 12:56終値2025/08/08 00:00収益2025/06/30年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Palatin Technologies, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Scott HenryAlliance Global PartnersJohn NewmanCanaccord GenuityI-Eh JenLaidlaw & Company (UK) Ltd4 その他のアナリストを表示
お知らせ • May 14Palatin Technologies, Inc. to Report Q3, 2026 Results on May 13, 2026Palatin Technologies, Inc. announced that they will report Q3, 2026 results on May 13, 2026
お知らせ • Nov 06Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $15.799999 million.Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $15.799999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,430,769 Price\Range: $6.5 Security Name: Series J Common Warrants Security Type: Equity Warrant Securities Offered: 2,430,769 Security Name: Series K Common Warrants Security Type: Equity Warrant Securities Offered: 2,430,769 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 2,430,769
お知らせ • Oct 01Palatin Technologies, Inc. has filed a Follow-on Equity Offering.Palatin Technologies, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,492,537 Security Name: Series J Common Warrants Security Type: Equity Warrant Securities Offered: 1,492,537 Security Name: Series K Common Warrants Security Type: Equity Warrant Securities Offered: 1,492,537 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 1,492,537
お知らせ • Jul 15Palatin Technologies, Inc. Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of ObesityPalatin Technologies, Inc. announced strong preclinical results for PL7737, an oral selective melanocortin-4 receptor (MC4R) agonist, showing effectiveness in rodent models of obesity. The preclinical study evaluated the weight loss effects of three oral doses of PL7737, both alone and in combination with tirzepatide (a GLP-1/GIP agonist), in a diet-induced obese (DIO) rat model. After 4 days of treatment, all results were statistically significant compared to vehicle control: PL7737 - Middle Dose: 5% weight loss, PL7737 - High Dose: 10% weight loss, Tirzepatide Alone: 5% weight loss,PL7737 Middle Dose + Tirzepatide: 11% weight loss. PL7737 High Dose + TirzepATide: 15% weight loss. Earlier this year, Palatin reported positive Phase 2 results from a study evaluating the combination of bremelanotide (an MC4R agonist) and tirzepatide (a GLP-1/G IP agonist). The study met its primary endpoint over the 8-week treatment period with highly statistically significant results. Additionally, Palatin announced that the FDA granted orphan drug designation to PL7737 for the treatment of leptin receptor (LEPR) deficiency-related obesity, a rare genetic disorder that disrupts MC4R signaling due to mutations in the LEPR gene. The leptin-melanocortin pathway, located in the hypothalamus, regulates hunger, energy balance, and body weight.
お知らせ • Jul 10Nyse American LLC Affirms the Decision of the Staff of NYSE American to Initiate Delisting Proceedings of the Palatin Technologies, Inc. Common StockOn July 7, 2025, Palatin Technologies, Inc. received written notification from NYSE American LLC stating that a Listing Qualifications Panel of the Exchange’s Committee for Review had unanimously determined to affirm the decision of the staff of NYSE American to initiate delisting proceedings of the Company’s common stock pursuant to Sections 1003(a) and 1003(f)(v) of the NYSE American Company Guide. A hearing on the proposed delisting was held before the Panel on June 18, 2025. The Company intends to exercise its right to have the full Committee for Review reconsider the Panel’s decision. A written request for such review must be submitted and received by the Exchange within 15 calendar days of the date of Panel’s written notification. The Company is actively working to resolve the NYSE American listing deficiencies prior to the appeal hearing before the full Committee for Review, which is expected to take place in late August or September 2025.
お知らせ • Jun 19Palatin Technologies, Inc., Annual General Meeting, Jul 25, 2025Palatin Technologies, Inc., Annual General Meeting, Jul 25, 2025.
お知らせ • Jun 14Palatin Technologies, Inc. announced that it has received $0.34 million in fundingOn June 13, 2025, Palatin Technologies, Inc. closed the transaction.
Board Change • May 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. Independent Director Tony Manning was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.